Novo Nordisk A/S ADR (NVO) — closed signal from July 15, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 13, 2025.
Predicted vs. what happened
What happened
Reached 32% of the predicted growth at its peak, without hitting the target.
The thesis — published July 15, 2025
Shares have been hovering around their long-term average price for two weeks while investor mood stays very upbeat. Demand for the companys GLP-1 diabetes drugs is rising quickly; Europe alone could be a $14 billion market by 2034. New clinical results and pricing approvals in Spain and Italy are expected before October. Because the stock trades at only 17 times expected earnings, it looks cheap for a growth company and might reach about $78 within the next quarter.
Primary drivers
- Price holding its long-term average hints it may rest briefly before rising again
- More people want the companys key medicines than it can make, suggesting years of growth
- Upcoming trial results and European price approvals could spark fresh interest soon
- Shares cost less than the wider market based on earnings, giving some downside cushion
How it played out
NVO: target was not reached
Lyra published NVO on 2025-07-15 at $68.17 with 13% expected growth. The thesis pointed to the stock holding near its long-term average, strong demand for key diabetes medicines, expected trial results and European price approvals before October, and a valuation of 17 times expected earnings.
Inside the window, the stock rose to a peak of $71 on 2025-07-25, a 4.1% gain. It stayed below the $76.17 target and never reached it. By 2025-10-13, it ended at $57.50. The thesis partially played out only in the early move, then missed the target.
What happened during the window
On 2025-07-29, Novo Nordisk cut its 2025 sales growth outlook and named Maziar Mike Doustdar as president and CEO. On 2025-09-10, the company announced a restructuring plan with 9,000 job cuts and lowered its 2025 profit forecast.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.